Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$0.9200
0.021.93%
At close: -
$0.9198
-0.00020-0.02%
After Hours: May 23, 6:56 PM EDT
Comments
Loading...
Sutro Biopharma Analyst Ratings and Price Targets | NASDAQ:STRO | Benzinga
Sutro Biopharma Inc has a consensus price target of $7.58 based on the ratings of 11 analysts. The high is $17 issued by JMP Securities on December 11, 2024. The low is $0.8 issued by B of A Securities on May 19, 2025. The 3 most-recent analyst ratings were released by B of A Securities, HC Wainwright & Co., and HC Wainwright & Co. on May 19, 2025, April 29, 2025, and March 17, 2025, respectively. With an average price target of $1.6 between B of A Securities, HC Wainwright & Co., and HC Wainwright & Co., there's an implied 73.95% upside for Sutro Biopharma Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
B of A Securities
HC Wainwright & Co.
HC Wainwright & Co.
Wedbush
Wells Fargo
1calculated from analyst ratings
Analyst Ratings for Sutro Biopharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/19/2025 | Buy Now | -13.02% | B of A Securities | Tazeen Ahmad55% | $1 → $0.8 | Maintains | Underperform | Get Alert |
| 04/29/2025 | Buy Now | 117.44% | HC Wainwright & Co. | Andres Maldonado44% | $2 → $2 | Reiterates | Neutral → Neutral | Get Alert |
| 03/17/2025 | Buy Now | 117.44% | HC Wainwright & Co. | Andrew Fein56% | $12 → $2 | Downgrade | Buy → Neutral | Get Alert |
| 03/14/2025 | Buy Now | — | Citizens Capital Markets | Reni Benjamin47% | — | Downgrade | Market Outperform → Market Perform | Get Alert |
| 03/14/2025 | Buy Now | 117.44% | Wedbush | David Nierengarten61% | $8 → $2 | Downgrade | Outperform → Neutral | Get Alert |
| 03/14/2025 | Buy Now | 8.72% | B of A Securities | Tazeen Ahmad55% | $11 → $1 | Downgrade | Buy → Underperform | Get Alert |
| 12/11/2024 | Buy Now | 334.88% | Wells Fargo | — | $5 → $4 | Maintains | Equal-Weight | Get Alert |
| 12/11/2024 | Buy Now | 1748.23% | JMP Securities | Reni Benjamin47% | $17 → $17 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 11/18/2024 | Buy Now | 1204.63% | HC Wainwright & Co. | Andrew Fein56% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 10/11/2024 | Buy Now | 1095.91% | Piper Sandler | Edward Tenthoff51% | $11 → $11 | Reiterates | Overweight → Overweight | Get Alert |
| 10/11/2024 | Buy Now | 1204.63% | HC Wainwright & Co. | Andrew Fein56% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 09/16/2024 | Buy Now | 1748.23% | JMP Securities | Reni Benjamin47% | $17 → $17 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 09/16/2024 | Buy Now | 1204.63% | HC Wainwright & Co. | Andrew Fein56% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 08/16/2024 | Buy Now | 1530.79% | Truist Securities | Asthika Goonewardene42% | $18 → $15 | Maintains | Buy | Get Alert |
| 08/14/2024 | Buy Now | 1204.63% | HC Wainwright & Co. | Andrew Fein56% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2024 | Buy Now | 987.19% | Oppenheimer | Jay Olson60% | $10 → $10 | Maintains | Outperform | Get Alert |
| 05/14/2024 | Buy Now | 1204.63% | HC Wainwright & Co. | Andrew Fein56% | $12 → $12 | Reiterates | Buy → Buy | Get Alert |
| 05/14/2024 | Buy Now | 769.75% | Wedbush | David Nierengarten61% | $8 → $8 | Reiterates | Outperform → Outperform | Get Alert |
| 05/08/2024 | Buy Now | 1204.63% | B of A Securities | Tazeen Ahmad55% | → $12 | Initiates | → Buy | Get Alert |
| 04/03/2024 | Buy Now | 1748.23% | JMP Securities | Reni Benjamin47% | $17 → $17 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 04/03/2024 | Buy Now | 1095.91% | Piper Sandler | Edward Tenthoff51% | $12 → $11 | Reiterates | Overweight → Overweight | Get Alert |
| 04/03/2024 | Buy Now | 987.19% | Oppenheimer | Jay Olson60% | $10 → $10 | Maintains | Outperform | Get Alert |
| 04/03/2024 | Buy Now | 1856.95% | Truist Securities | Asthika Goonewardene42% | $25 → $18 | Maintains | Buy | Get Alert |
| 03/28/2024 | Buy Now | 987.19% | Oppenheimer | Jay Olson60% | → $10 | Maintains | Outperform | Get Alert |
| 03/27/2024 | Buy Now | 987.19% | Oppenheimer | Jay Olson60% | $10 → $10 | Maintains | Outperform | Get Alert |
| 03/26/2024 | Buy Now | 1748.23% | JMP Securities | Reni Benjamin47% | $17 → $17 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/26/2024 | Buy Now | 769.75% | Wedbush | David Nierengarten61% | $12 → $8 | Maintains | Outperform | Get Alert |
| 03/26/2024 | Buy Now | 1204.63% | HC Wainwright & Co. | Andrew Fein56% | $16 → $12 | Maintains | Buy | Get Alert |
| 11/15/2023 | Buy Now | 1204.63% | Piper Sandler | Edward Tenthoff51% | $18 → $12 | Maintains | Overweight | Get Alert |
| 11/14/2023 | Buy Now | 1639.51% | HC Wainwright & Co. | Andrew Fein56% | → $16 | Reiterates | Buy → Buy | Get Alert |
| 11/09/2023 | Buy Now | 1204.63% | Deutsche Bank | James Shin34% | → $12 | Initiates | → Buy | Get Alert |
| 10/23/2023 | Buy Now | 1204.63% | Wedbush | David Nierengarten61% | → $12 | Reiterates | Outperform → Outperform | Get Alert |
| 10/06/2023 | Buy Now | 987.19% | Oppenheimer | Jay Olson60% | → $10 | Initiates | → Outperform | Get Alert |
| 09/06/2023 | Buy Now | 2617.98% | Truist Securities | Asthika Goonewardene42% | → $25 | Reiterates | Buy → Buy | Get Alert |
| 08/14/2023 | Buy Now | 1748.23% | JMP Securities | Reni Benjamin47% | → $17 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 08/11/2023 | Buy Now | 1639.51% | HC Wainwright & Co. | Andrew Fein56% | → $16 | Reiterates | Buy → Buy | Get Alert |
| 08/11/2023 | Buy Now | 1204.63% | Wedbush | David Nierengarten61% | $20 → $12 | Maintains | Outperform | Get Alert |
| 06/27/2023 | Buy Now | 1748.23% | JMP Securities | Reni Benjamin47% | → $17 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 06/12/2023 | Buy Now | 1748.23% | JMP Securities | Reni Benjamin47% | → $17 | Reiterates | → Market Outperform | Get Alert |
| 05/17/2023 | Buy Now | 1748.23% | JMP Securities | Reni Benjamin47% | → $17 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 05/16/2023 | Buy Now | 1639.51% | HC Wainwright & Co. | Andrew Fein56% | → $16 | Reiterates | Buy → Buy | Get Alert |
| 04/03/2023 | Buy Now | 1748.23% | JMP Securities | Reni Benjamin47% | $20 → $17 | Maintains | Outperform | Get Alert |
| 03/31/2023 | Buy Now | 2074.39% | Wedbush | David Nierengarten61% | → $20 | Reiterates | → Outperform | Get Alert |
| 03/31/2023 | Buy Now | 1639.51% | HC Wainwright & Co. | Andrew Fein56% | $20 → $16 | Maintains | Buy | Get Alert |
| 01/13/2023 | Buy Now | 2617.98% | Truist Securities | Asthika Goonewardene42% | $21 → $25 | Maintains | Buy | Get Alert |
| 01/10/2023 | Buy Now | 1856.95% | Piper Sandler | Edward Tenthoff51% | $16 → $18 | Maintains | Overweight | Get Alert |
| 11/09/2022 | Buy Now | 2074.39% | HC Wainwright & Co. | Andrew Fein56% | $30 → $20 | Maintains | Buy | Get Alert |
| 08/23/2022 | Buy Now | 2183.11% | Truist Securities | Asthika Goonewardene42% | $37 → $21 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Sutro Biopharma (STRO) stock?
The latest price target for Sutro Biopharma (NASDAQ:STRO) was reported by B of A Securities on May 19, 2025. The analyst firm set a price target for $0.80 expecting STRO to fall to within 12 months (a possible -13.02% downside). 15 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Sutro Biopharma (STRO)?
The latest analyst rating for Sutro Biopharma (NASDAQ:STRO) was provided by B of A Securities, and Sutro Biopharma maintained their underperform rating.
When was the last upgrade for Sutro Biopharma (STRO)?
There is no last upgrade for Sutro Biopharma
When was the last downgrade for Sutro Biopharma (STRO)?
The last downgrade for Sutro Biopharma Inc happened on March 17, 2025 when HC Wainwright & Co. changed their price target from $12 to $2 for Sutro Biopharma Inc.
When is the next analyst rating going to be posted or updated for Sutro Biopharma (STRO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sutro Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sutro Biopharma was filed on May 19, 2025 so you should expect the next rating to be made available sometime around May 19, 2026.
Is the Analyst Rating Sutro Biopharma (STRO) correct?
While ratings are subjective and will change, the latest Sutro Biopharma (STRO) rating was a maintained with a price target of $1.00 to $0.80. The current price Sutro Biopharma (STRO) is trading at is $0.92, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
